Patients' preferences for accepting risks and uncertainty in AML treatments within European public health care systems: a cross-sectional study in Finland, Italy, and Germany.

Authors

Åsa Grauman, Jennifer Viberg Johansson, Mika Kontro, Karl Haller, Sari Kytölä, Karin Groothuis-Oudshoorn, Samantha Nier, Caroline A Heckman, Giovanni Marconi, Chiara Zingaretti, Giovanni Martinelli, Giorgia Simonetti, Lars Bullinger, Ulrik Kihlbom

Published in

Leukemia & lymphoma. Pages 1-11. Oct 28, 2026. Epub Oct 28, 2026.

Abstract

The aim of this study was to identify what tradeoffs patients with acute myeloid leukemia (AML) are willing to make between different treatment attributes when choosing between chemotherapy and novel targeted therapies involving higher uncertainty, within the context of European publicly funded health‑care systems. A survey with a probabilistic threshold technique and a ranking exercise were distributed to patients with AML in Finland, Germany, and Italy. Respondents (n = 68) were presented with two treatment options described by six attributes. Interval regressions were used to analyze the threshold intervals for each attribute. Mean threshold values for accepting targeted treatment were 82% chance of complete remission, 48% risk of short-term side effects, 10% for long-term side effects, and two weeks for treatment time in hospital. Preference heterogeneity was identified. Complete remission was ranked most important followed by scientific evidence and risk of long-term side effects.

PMID:
42952224
Bibliographic data and abstract were imported from PubMed on 29 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.